Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy

Table 1 Baseline characteristics and therapeutic outcomes in all patients who underwent gastric endoscopic submucosal dissection

	All patients (n = 597)
Age, mean (SD), yr	72.3 (8.815)
Sex, male, n (%)	414 (69.3)
BMI, mean (SD), yr	22.6 (3.424)
Comorbidity, n (%)	379 (63.5)
Hypertension	307 (51.4)
Diabetes mellitus	114 (19.1)
Renal failure	17 (2.8)
Coronary artery diseases	142 (23.8)
Longitudinal location, n (%)
Upper	90 (15.1)
Middle	250 (41.9)
Lower	257 (43.0)
Macroscopic findings, n (%)
Depressed	275 (46.1)
Non-depressed	322 (53.9)
Pathological findings, n (%)1
Differentiated	578 (96.8)
Undifferentiated	19 (3.2)
Depth of invasion, n (%)
Mucosa	530 (88.8)
Submucosa	67 (11.2)
LDA intake, n (%)	154 (25.8)
Continuous LDA	95 (16.4)
Continuous single-LDA	56 (9.3)
DAPT (LDA with clopidogrel), n (%)	59 (9.9)
Continuous LDA on DAPT, n (%)	39 (6.5)
Specimen size, median (IQR), mm	32.9 (24-40)
Complete resection, n (%)	557 (93.3)
Curative resection, n (%)	524 (87.8)
Postoperative bleeding, n (%)	41 (6.9)
Delayed bleeding	16 (2.7)

¹Differentiated, adenoma/well or moderately differentiated adenocarcinoma/papillary adenocarcinoma; undifferentiated, signet-ring cell carcinoma/poorly differentiated adenocarcinoma/mucinous adenocarcinoma. BMI: Body mass index; DAPT: Dual antiplatelet therapy; ESD: Endoscopic submucosal dissection; IQR: Interquartile range; LDA: Low-dose aspirin; SD: Standard deviation.